ERBB2 and cancer: Fortunately, advancements over the last two decades in the development of HER2-targeted agents and their clinical application has revolutionized the prognosis of patients with HER2 (+) cancer; median progression-free survival in the 1st line setting has been extended to 18.7 months with dual-target agents from 4.6 months with chemotherapy only [6].